Tirzepatide
Also: LY3298176, GIP/GLP-1 dual receptor agonist, twincretin
This profile summarizes research context only. It is not medical advice and does not describe how to use this compound in humans or animals — no dosing, administration, or protocols. Learn more
Tirzepatide is a synthetic, single-chain peptide engineered as a dual agonist of the GIP and GLP-1 incretin receptors, sometimes referred to in the research literature as a "twincretin." It is discussed primarily in the context of incretin receptor signaling, glucose-dependent insulin secretion, and energy-balance pathways, and is associated with a comparatively large body of published literature relative to most research peptides. This profile is provided strictly for research and educational reference; it does not describe how the compound is used and makes no health, safety, or efficacy claims. Available evidence spans mechanistic, in-vitro, animal, and human pharmacology work and should be interpreted in light of study design and translational limitations.
Mechanism as described in the literature
Tirzepatide is a synthetic peptide based on the GIP sequence and modified with a fatty-diacid moiety that promotes albumin binding and extends its circulating half-life. In receptor-pharmacology studies it is characterized as a dual agonist that engages both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, two class B G-protein-coupled receptors within the incretin system.
Mechanistic and preclinical work describes downstream signaling through cAMP/PKA and related pathways, with effects on glucose-dependent insulin secretion and appetite/energy-balance circuits reported in cell and animal models. The relative contribution of GIP- versus GLP-1-receptor activity, the role of biased signaling, and how these mechanisms translate across species and contexts remain active areas of investigation. These are descriptions of receptor-level and model-system findings and do not, on their own, establish any outcome.
Research areas
- Incretin receptor pharmacology (GIP and GLP-1 receptor signaling)
- Glucose-dependent insulin secretion and beta-cell biology in vitro and in animal models
- Appetite, energy balance, and metabolic regulation pathways
- Comparative dual-agonist vs single-agonist mechanism studies
- Peptide engineering: half-life extension and receptor selectivity/bias
Documentation notes
References
Frequently asked questions
What is tirzepatide classified as?+
In the research literature it is described as a dual GIP/GLP-1 receptor agonist (sometimes called a "twincretin"), an engineered incretin peptide. It is commonly referenced by the research code LY3298176.
Is there human research on it?+
Tirzepatide is associated with a comparatively large published pharmacology research literature relative to most research peptides, including human pharmacology work. This profile is educational only and does not summarize outcomes, dosing, or use; all evidence should be read with attention to study design and translation limits.
Does this profile describe how to use tirzepatide?+
No. This is a research-use-only educational reference. It contains no dosing, administration, reconstitution, or usage instructions and makes no safety or efficacy claims.